Navigation Links
A Recent Study by ITG's Majestic Market Research Indicates a Strong Launch for Gilenya in Spite of Its Time-Consuming Initiation Process
Date:6/1/2011

NEW YORK, June 1, 2011 /PRNewswire/ -- A study published this week by ITG's Majestic Market Research revealed that Novartis' recently approved drug, Gilenya, continues to steal share from market leaders in the multiple sclerosis (MS) market, and uptake is expected to increase significantly over the next year.  Gilenya came onto the market in late September 2010 as the first FDA-approved oral disease-modifying MS drug.  Despite negative sentiment around Gilenya's lengthy initiation process, neurologists are embracing the new drug at an impressive rate.  Real time data from ITG's proprietary physician panel indicate that Gilenya was the disease-modifying treatment of choice for 20% of new written MS prescriptions in April.  Furthermore, surveyed neurologists indicated that their prescribing of Gilenya will increase significantly over the course of 2011 as they continue to shift inadequate responders from other MS therapies to the new drug.

The study takes an in-depth look at how Gilenya's multi-step initiation process is impacting neurologists' use of the drug.  According to neurologists, new treatment starts for Gilenya typically take between three to six weeks and involve the scheduling and organization of prescreening tests and ongoing monitoring for adverse events.  

Physicians reported that Novartis plays an important role in facilitating these steps. In fact, 63% of Gilenya prescribers indicated that they receive support from Novartis during this process, and 25% of them classified this assistance as superior to what competing companies offer for their products.  

By comparison, neurologists appear unable to get over similar concerns about Acorda Therapeutics' Ampyra, which was launched in March 2010 as the first FDA approved drug to improve walking in MS patients. Like Gilenya, Ampyra is associated with an onerous initi
'/>"/>

SOURCE ITG
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
2. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
3. Studies Attribute Recent Increase in Multiple Myeloma Survival to Novel Therapies
4. Recent Findings from the Framingham Offspring Study Show Low Numbers of LDL Particles (LDL-P) by NMR are Associated With Fewer Heart Disease Related Events than Equivalently Low Levels of LDL Cholesterol (LDL-C).(1)
5. Recent Studies Suggest Popular Diet Pill Relacore Reduces Acne Breakouts
6. Alegent Health Sees Positive Results From Recent Clinician Usability Study Collaboration With Siemens and Motion Computing
7. Recent Data Study Suggests Cortisol Could Help Alleviate Suffering for Those With Chronic Fatigue Syndrome and Fibromyalgia
8. Recent siRNA Research Publications Support Silence Therapeutics Combined Development Approach
9. Senesco Expands on Recently Announced Preclinical Pancreatic Islet Data
10. New Analysis Shows Efficacy of REMICADE(R) in Treatment of Ulcerative Colitis in Patients with Recent Disease Onset or Long-Standing Disease
11. Presentations From Recent Heart Rhythm Society Meeting Validate the Safety and Efficacy of Ablation Frontiers Technology in 230 Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... BUENA, N.J. , Dec. 17, 2014  IGI ... announced today the closing of its offering of $125 ... due 2019 (the "Notes").  The Notes were offered and ... 144A under the Securities Act of 1933, as amended ... at a fixed rate of 3.75% per year, payable ...
(Date:12/17/2014)... Dec. 17, 2014 PCCA received the ... ( http://bit.ly/1382OkS ) program seal for best practices ... program highlights medical practices, materials and goods that ... Children affected by autism often have ... exacerbated by ingredients found in food and medicine ...
(Date:12/15/2014)... , Dec. 12, 2014 Research and Markets ... of the "Electrocardiogram (ECG) Devices - Global Trends, ... http://photos.prnewswire.com/prnh/20130307/600769 ... US$330 million by 2016. The North America ... global market share while Europe ...
Breaking Medicine Technology:IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 2IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 3IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 4Parents Of Children With Autism Spectrum Disorder Have New Options When Administering Medications 2Parents Of Children With Autism Spectrum Disorder Have New Options When Administering Medications 3Electrocardiogram (ECG) Devices - Global Trends, Estimates and Forecasts, 2012-2018 2Electrocardiogram (ECG) Devices - Global Trends, Estimates and Forecasts, 2012-2018 3Electrocardiogram (ECG) Devices - Global Trends, Estimates and Forecasts, 2012-2018 4
... April 27, 2012  Hill-Rom Holdings, Inc. (NYSE: HRC ... the Deutsche Bank Securities Health Care Conference in Boston on ... are invited to listen to the live discussion via the ... at http://www.media-server.com/m/p/2sfzaj9g . A recorded replay of the discussion ...
... Presented today by Tribeca Film Festival co-founder Craig ... Professor Clay Christensen and the Disruptor Foundation, Hanger ... CP, FAAOP and Area Practice Manager Dan Strzempka, ... Award.  Carroll and Strzempka received the award for ...
Cached Medicine Technology:Hanger clinicians honored with 2012 Tribeca Disruptive Innovation Award 2
(Date:12/17/2014)... This prestigious award is given ... made outstanding and innovative contributions to the physical ... private practice physical therapy by the Private Practice ... On behalf of Performance Physical Therapy, Michelle Collie ... Performance accepted the award at the Private Practice, ...
(Date:12/17/2014)... 17, 2014 In its comprehensive analysis ... its Argus Claim Review division have recently identified out-of-network ... common ways savings are achieved on behalf of employer-clients. ... of dollars in savings to Argus each year, with ... As explained by Tom Doney, Cypress president and CEO, ...
(Date:12/17/2014)... Project Veritas is releasing a video interview ... economist and Obamacare architect Jonathan Gruber to public attention. ... interview, which is being distributed on YouTube. , During ... in the Affordable Care Act in order to hide ... dollar per year tax grab. , “President Obama promised ...
(Date:12/17/2014)... 2014 (HealthDay News) -- Expectant parents should leave prenatal ... Administration recommends. Use of ultrasound imaging and heartbeat ... entirely risk-free, the agency warns. "Although there ... to ultrasound imaging and heartbeat monitors, prudent use of ... Shahram Vaezy, an FDA biomedical engineer, said in an ...
(Date:12/17/2014)... HealthDay Reporter TUESDAY, Dec. 16, 2014 ... a new study reveals that states that routinely perform randomized ... on their roads. The finding suggests that states that ... deter inebriated revelers from getting behind the wheel in the ... regarding drinking and driving," said study lead author James Fell, ...
Breaking Medicine News(10 mins):Health News:Performance Physical Therapy Awarded with Jayne L. Snyder Private Practice of the Year 2014 2Health News:Out-of-Network & Medical Necessity Reviews among Top Ways TPA Identifies Significant Medical Claim Savings 2Health News:Project Veritas: James O’Keefe Interviews the Man Who Discovered Jonathan Gruber Videos 2Health News:FDA Warns Against Fetal 'Keepsake' Videos 2Health News:Enforcement of Drunk Driving Laws Makes Roads Safer, Study Finds 2Health News:Enforcement of Drunk Driving Laws Makes Roads Safer, Study Finds 3
... proven effective, tamoxifen could be new way to fight ... drug used to help prevent recurring breast cancer appears to ... research has found. , University of Rochester Medical Center researchers ... infections, which can be fatal to people with compromised ...
... NEW YORK, July 24 Empire BlueCross BlueShield and Stony ... reached agreement for a new contract, effective August 1, 2009. ... access to Stony Brook Hospital as in-network. , ... the long-standing relationship we have with Stony Brook," noted Mark ...
... WASHINGTON, July 24 Speaker Nancy Pelosi issued ... to fund the Departments of Labor, Health and Human Services, Education, ... federal funding for needle exchange, passed in the House by a ... "The fiscal year 2010 Labor-Health and Human Services-Education appropriations ...
... , , WEST ... Hollywood will never go away. Despite the poor economy, a ... the American Society of Plastic Surgeons. One would think the ... to take better care of their skin, but unfortunately summertime in ...
... , , , PORTLAND, ... has selected Artefill, the first and only FDA-approved microsphere-enhanced collagen filler for ... user the past several years due to its proven success and effectiveness ... , Dr. Vu commented, "Artefill is a great product for ...
... , , , LANCASTER, ... 32 filed cases around the country have filed a joint motion asking ... Judge James G. Carr of the United States District Court for the ... 2009, before the Judicial Panel on Multidistrict Litigation in Washington, D.C. , ...
Cached Medicine News:Health News:Breast Cancer Drug May Beat Fungal Infection 2Health News:Pelosi Statement on House Passage of Labor, HHS, Appropriations Bill, Which Lifts Ban on Needle Exchange 2Health News:It Isn't Just Vanity! Local MedSpa Seeks to Correct and Educate. 2Health News:Dr. Kim-Chi Vu in Portland Selects Artefill to Meet Growing Patient Demand for a Longer Lasting Dermal Filler 2Health News:Dr. Kim-Chi Vu in Portland Selects Artefill to Meet Growing Patient Demand for a Longer Lasting Dermal Filler 3Health News:Motion Filed to Consolidate Yasmin/YAZ Litigation in Toledo, Ohio 2